IMUX Stock Forecast is $14

IMUX Stock Forecast for the next 12 months is $14

---

IMUX Stock Forecast: Price today

IMUX Stock Forecast: Latest News

Immunic failed in Phase 1 b psoriasis trial: Immunic failed in its Phase 1 b psoriasis trial of IMU-935 where it saw a high placebo rate and failed to separate two active arms from the placebo. However, they found a greater decrease than expected in Psoriasis Area and Severity Index (PASI). The trial was carried out on 41 patients and the primary objective was to demonstrate the safety and tolerability of IMU-935.

Why is the stock price decreasing?

The stock price is seen to be decreasing recently after its increase of 150% due to its $60 million oversubscribed private placement equity financing deal. The primary reason for its decrease in stock price can be seen as the Phase 1 b trial failure. This failure saw an immediate downfall of 74% in the stock price, so, as we mentioned before the company has to focus on bringing out more positive results on its trials and needs to stand out in the competition to see a high in the stock price.

IMUX Stock Forecast: Q2 Results

• IMUX released its Quarter 2 (which ended on June 2022) in August 2022.
• The company’s operating expenses were reported as $20.6 million, which increased by 7.5% from $19.2 million in the same quarter, the previous year.
• The company’s operating income decreased by 7.5% over a year and was reported as -$20.6 million.
• Earnings from continuing operations were declared as -$21.9 million, down 22.1% YoY.
• Research and development expenses were $16.5 million, up 5%.
• Its net income was -$21.9 million, down 22.1% YoY.
• Diluted earnings per share (EPS) were declared as -$0.72, down 12.2% YoY.
• Its EBIT was declared as -$20.6 million, down 7.51% YoY.

IMUX Stock Price Prediction for the next 12 months

Average IMUX Stock Forecast for the next 12 Months	$14
SVB Leerink	$5
Wedbush	$11
HC Wainwright	$26

IMUX Stock Forecast Today

IMUX Stock Forecast: Conclusion

The recent financing led to a sudden increase in the stock price, which is the highest in the past 6 months. The company after its two major failures in the previous years has shown quite a progress in the phase-2 trial of vidofludimus calcium (IMU-838) for patients with multiple sclerosis which was noteworthy, but there is a lot to do in the Multiple sclerosis market with numerous players. So, this can be considered a good investment but the company has to focus on driving more positive results and should stand out in the market.

Writer

Bommu Vaishnavi

Gold Price Forecast: Gold Price Rises above $1,650, Outlook Turns Bullish?

Note: Crowdwisdom360 collates Predictions and data from all over the net and has no in-house view on the likely trends in the Stocks or Crypto Coins. Please consult a registered investment advisor to guide you on your financial decisions.